{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:22:52Z","timestamp":1791595372616,"version":"4.3.4"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"\n Background:<\/jats:title>\n \n Although some new treatment protocols have been developed, 7+3 chemotherapy is still the most widely used treatment for acute myeloid leukemia (AML) induction therapy. Granulocyte colony-stimulating factor (G-CSF) is a widely used treatment modality for myelosuppression after chemotherapy as it accelerates myeloid healing and reduces the incidence and severity of fever and infections. Most current guidelines recommend primary G-CSF prophylaxis in solid cancer patients with a risk of \u226520% febrile neutropenia. However, the use of G-CSF in the induction treatment of AML is controversial as it increases the proliferation of leukemic blasts\n in vitro<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n This study was to investigate the effects of G-CSF use in AML induction therapy on survival.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n The study group included 36 patients over the age of 18 with bone marrow blast rate >20% who were diagnosed with AML [M\n 0<\/jats:sub>\n -M\n 5<\/jats:sub>\n according to FAB (French-American-British) classification] using diagnostic tests, such as flow cytometry and bone marrow biopsy between 2016 and 2020. Eighteen of these patients were from a center that employed prophylactic G-CSF during induction therapy, and the remaining 18 patients were from another center that did not employ prophylactic G-CSF during induction therapy. The characteristics of the patients were reviewed retrospectively from their files. The induction therapy used was 7+3 (7-day cytarabine +3-day idarubicin) chemotherapy regimen.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Although not reaching statistically significant levels, the use of G-CSF in AML induction therapy was found to provide both OS and PFS advantages. In addition, patients who used G-SF had statistically significantly fewer intensive care unit (ICU) stays than those who did not use it.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Although the use of G-CSF in induction therapy of AML patients did not significantly increase survival rates, it caused a statistically significant decrease in the need for intensive care. However, larger-scale studies with longer follow-up periods are needed to confirm the results of this study.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/njcp.njcp_607_24","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:01:11Z","timestamp":1744358471000},"page":"325-330","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Effects of Adding G-CSF to the Induction Therapy of Patients with AML Being Treated with the 7+3 Protocol: A Retrospective Comparative Study"],"prefix":"10.4103","volume":"28","author":[{"given":"A","family":"Eser","sequence":"first","affiliation":[{"name":"Department of Hematology, Gaziantep Medical Point Hospital, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Atasehir Medicana Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"R1-20260423","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjh.12233","article-title":"Anthracyclines during induction therapy in acute myeloid leukaemia: A systematic review and meta-analysis","volume":"161","author":"Teuffel","year":"2013","journal-title":"Br J Haematol"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/cncr.20532","article-title":"Death during induction therapy and first remission of acute leukemia in childhood: The St. Jude experience","volume":"101","author":"Rubnitz","year":"2004","journal-title":"Cancer"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): The first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/bjc.1987.151","article-title":"Effects of recombinant human granulocyte colony-stimulating factor (G-CSF) on blast progenitors from acute myeloblastic leukemia patients","volume":"56","author":"Nara","year":"1987","journal-title":"Br J Cancer"},{"key":"R6-20260423","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/stem.5530130609","article-title":"Granulocyte colony-stimulating factor in acute myeloid leukemia","volume":"13","author":"Usuki","year":"1995","journal-title":"Stem Cells"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1996.14.7.2150","article-title":"Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group","volume":"14","author":"Zittoun","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"R8-20260423","article-title":"Myeloid Growth Factors [Version 2.2017], NCCN Clinical Practice Guidelines in Oncology","volume":"15","year":"2017","journal-title":"Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw"},{"key":"R9-20260423","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","article-title":"A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia","volume":"90","author":"Heil","year":"1997","journal-title":"Blood"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002770050425","article-title":"Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia","volume":"77","author":"Kern","year":"1998","journal-title":"Ann Hematol"},{"key":"R11-20260423","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03251.x","article-title":"Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: A multicentre randomized study","volume":"116","author":"Usuki","year":"2002","journal-title":"Br J Haematol"},{"key":"R12-20260423","first-page":"32","article-title":"Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia","volume":"10","author":"Maslak","year":"1996","journal-title":"Leukemia"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","article-title":"A double blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A southwest oncology group study (9031)","volume":"91","author":"Godwin","year":"1998","journal-title":"Blood"},{"key":"R14-20260423","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.02.003","article-title":"Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies","volume":"57","author":"Kang","year":"2017","journal-title":"Leuk Res"},{"key":"R15-20260423","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.V82.8.2278.2278","article-title":"Beyond supportive care: What are the next question in the use of hematopoietic cytokines with cytotoxic chemotherapy?","volume":"82","author":"Demetri","year":"1993","journal-title":"Blood"},{"key":"R16-20260423","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1056\/NEJM199506223322504","article-title":"A controlled study of recombinant human granulocyte colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia","volume":"332","author":"Dombret","year":"1995","journal-title":"New Engl J Med"},{"key":"R17-20260423","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01737421","article-title":"In vitro response of blasts to IL-3, GM\u2013CSF, and G-CSF is different for individual AML patients: Factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity","volume":"68","author":"Van der Lely","year":"1994","journal-title":"Ann Hematol"},{"key":"R18-20260423","first-page":"749","article-title":"Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs","volume":"8","author":"Tafuri","year":"1994","journal-title":"Leukemia"},{"key":"R19-20260423","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00432-006-0115-7","article-title":"Impairment in functional status and survival in patients with acute myeloid leukaemia","volume":"132","author":"Wedding","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"R20-20260423","first-page":"Ecr28","article-title":"Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature","volume":"88","author":"Piccaluga","year":"2003","journal-title":"Haematologica"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_607_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:27:45Z","timestamp":1786724865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_607_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_607_24","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}